Abstract
Biologic therapies have revolutionized the treatment of immune-mediated inflammatory diseases but are associated with an increased risk of serious and opportunistic infections, including tuberculosis and nontuberculous mycobacterial disease. Despite this increased risk, the overall risk-benefit ratio remains favorable with appropriate screening and risk assessment. Further population-based studies are needed to establish the risk of tuberculosis and nontuberculous mycobacterial disease with the new biologics. This article highlights the incidence and drug-specific risk of tuberculous and nontuberculous mycobacterial infection in the setting of biologics, screening and prevention, and treatment of latent tuberculosis in this setting.
Original language | English (US) |
---|---|
Pages (from-to) | 413-423 |
Number of pages | 11 |
Journal | Infectious Disease Clinics of North America |
Volume | 34 |
Issue number | 2 |
DOIs | |
State | Published - Jun 2020 |
Keywords
- Biologics
- Mycobacteria
- Opportunistic infection
- Tuberculosis
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases